NKG2DL surface expression by leukemic cells. PBMCs from 6 patients with different hematopoietic malignancies were stained for NKG2DL expression with AMO1 (MICA), BMO1 (MICB), AUMO1 (ULBP1), BUMO2 (ULBP2), and CUMO2 (ULBP3), respectively, and investigated by FACS. Malignant cells were selected as described in “Patients, materials, and methods.” Shaded histograms represent expression of the indicated NKG2DL, and dotted lines show staining with the respective isotype control.